Novartis VAY736: A subject, investigator, and sponsor blinded randomized placebo controlled multicenter study to investigate VAY736 in patients with idiopathic pulmonary fibrosis

Administered By

Awarded By

Contributors

Start/End

  • June 19, 2018 - July 30, 2022